Longley, D.B. & Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol. 205, 275–292 (2005).
Wang, T.L. et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl. Acad. Sci. USA 101, 3089–3094 (2004).
Schmitt, C.A., Rosenthal, C.T. & Lowe, S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med. 6, 1029–1035 (2000).
Helmrich, A. et al. Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo. Oncogene 24, 4174–4182 (2005).
Redmond, K.M., Wilson, T.R., Johnston, P.G. & Longley, D.B. Resistance mechanisms to cancer chemotherapy. Front. Biosci. 13, 5138–5154 (2008).
Wilson, T.R., Longley, D.B. & Johnston, P.G. Chemoresistance in solid tumours. Ann. Oncol. 17 (suppl. 10), x315–x324 (2006).
Lee, S. & Schmitt, C.A. Chemotherapy response and resistance. Curr. Opin. Genet. Dev. 13, 90–96 (2003).
Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116–1120 (2008).
Kobayashi, H. et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA 90, 3294–3298 (1993).
Waldman, T. et al. Cell-cycle arrest versus cell death in cancer therapy. Nat. Med. 3, 1034–1036 (1997).
Samson, D.J., Seidenfeld, J., Ziegler, K. & Aronson, N. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 22, 3618–3630 (2004).
Croix, B.S. et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88, 1285–1296 (1996).
Kerbel, R.S. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev. 20, 1–2 (2001).
Wang, F. et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J. Natl. Cancer Inst. 94, 1494–1503 (2002).
Kim, J.J. & Tannock, I.F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 5, 516–525 (2005).
Trédan, O., Galmarini, C.M., Patel, K. & Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441–1454 (2007).
Garzotto, M., Myrthue, A., Higano, C.S. & Beer, T.M. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol. Oncol. 24, 254–259 (2006).
Beer, T.M. et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res. 10, 1306–1311 (2004).
Bavik, C. et al. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66, 794–802 (2006).
Coppé, J.P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
Clevers, H. Wnt/β-catenin signaling in development and disease. Cell 127, 469–480 (2006).
Binet, R. et al. WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res. 69, 9183–9191 (2009).
Acosta, J.C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).
Huang, S.M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
Thiery, J.P., Acloque, H., Huang, R.Y. & Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
Yook, J.I. et al. A Wnt-Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 8, 1398–1406 (2006).
Vincan, E. & Barker, N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin. Exp. Metastasis 25, 657–663 (2008).
Wu, K. & Bonavida, B. The activated NF-κB–Snail–RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit. Rev. Immunol. 29, 241–254 (2009).
Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415–428 (2007).
Bernard, D. et al. Involvement of Rel/nuclear factor-κB transcription factors in keratinocyte senescence. Cancer Res. 64, 472–481 (2004).
Berchtold, C.M., Wu, Z.H., Huang, T.T. & Miyamoto, S. Calcium-dependent regulation of NEMO nuclear export in response to genotoxic stimuli. Mol. Cell. Biol. 27, 497–509 (2007).
Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).
Kuilman, T. & Peeper, D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9, 81–94 (2009).
Fumagalli, M. & d'Adda di Fagagna, F. SASPense and DDRama in cancer and ageing. Nat. Cell Biol. 11, 921–923 (2009).
Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005).
Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).
Wajapeyee, N., Serra, R.W., Zhu, X., Mahalingam, M. & Green, M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363–374 (2008).
Coppé, J.P., Kauser, K., Campisi, J. & Beausejour, C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 281, 29568–29574 (2006).
Gilbert, L.A. & Hemann, M.T. DNA damage–mediated induction of a chemoresistant niche. Cell 143, 355–366 (2010).
Biswas, S. et al. Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117, 1305–1313 (2007).
Davis, A.J. & Tannock, J.F. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol. 1, 86–93 (2000).
Meads, M.B., Hazlehurst, L.A. & Dalton, W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 14, 2519–2526 (2008).
Shree, T. et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 25, 2465–2479 (2011).
DeNardo, D.G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).
Chien, Y. et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125–2136 (2011).
Alderton, P.M., Gross, J. & Green, M.D. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 52, 194–201 (1992).